Skip to content

Clinical study of fibrin glue assisted amniotic membrane in the treatment of rhegmatogenous retinal detachment

Clinical study of fibrin glue assisted amniotic membrane in the treatment of rhegmatogenous retinal detachment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096657
Enrollment
Unknown
Registered
2025-01-27
Start date
2024-04-03
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rhegmatogenous retina detachment (RRD)

Interventions

experimental group:Fibrin glue assisted amniotic membrane covering
control group:silicone oil tamponade

Sponsors

The Eye Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) RRD caused by inferior retinal breaks unsuitable for scleral buckling; (2) patients aged >=18 years old; (3) be able and willing to participate in clinical trials.

Exclusion criteria

Exclusion criteria: (1) received vitreoretinal surgery; (2) patients underwent scleral buckling surgery; (3) receiving gas injection; (4) proliferative vitreoretinopathy grade C or above; (5) patients without prone position after surgery; (6) not expected to be followed up at the designated clinical trial site; (7) patients with nervous system or mental diseases who cannot cooperate with the examination; (8) unable to obtain informed consent.

Design outcomes

Primary

MeasureTime frame
Retinal reattachment rate;best corrected visual acuity;

Secondary

MeasureTime frame
The recurrence rate of retinal detachment; incidence of high intraocular pressure;Incidence of macular anterior membrane;Incidence of endophthalmitis;

Countries

China

Contacts

Public ContactYong Wei

The Eye Hospital of Wenzhou Medical University

weiyongdoctor@163.com+86 150 5755 1266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026